医学
肺动脉高压
心脏病学
气道正压
内科学
重症监护医学
呼吸
血流动力学
疾病
氧气疗法
血压
气道
病理生理学
血管阻力
慢性阻塞性肺病
持续气道正压
临床试验
模式
麻醉
波生坦
呼吸生理学
呼吸道疾病
随机对照试验
通风(建筑)
前瞻性队列研究
作者
MARGEAUX LACAVERA,Aleezay Asghar,Joseph Ballard,Mohit Bandla,Dustin R. Fraidenburg
标识
DOI:10.1097/mcp.0000000000001307
摘要
PURPOSE OF REVIEW: Sleep-disordered breathing (SDB) is an increasingly recognized contributor to WHO Group 3 pulmonary hypertension (PH). This review examines the epidemiology and pathophysiology linking SDB to PH, evaluates the evidence base for sleep-directed therapies in modifying pulmonary hemodynamics, and highlights emerging treatment modalities that may be able to alter disease course. RECENT FINDINGS: The mechanisms underlying SDB-related PH are multifactorial, including recurrent nocturnal hypoxemia, altered intrathoracic pressures, and obesity-driven metabolic and inflammatory dysregulation. Positive airway pressure therapy remains the cornerstone of treatment of SDB-related PH, though mandibular advancement devices and hypoglossal nerve stimulation offer viable alternatives. Hypoxic burden, rather than apnea-hypopnea index alone, is increasingly recognized as a better predictor for cardiovascular and pulmonary vascular outcomes in SDB. Long-term oxygen therapy provides hemodynamic benefit in patients with resting hypoxemia, though evidence is limited in those with isolated nocturnal desaturation. SUMMARY: SDB is an underdiagnosed and clinically important contributor to PH. Early identification and treatment, particularly with positive airway pressure therapy when indicated, can meaningfully reduce pulmonary arterial pressures. Future research should prioritize prospective trials examining the direct impact of glucagon-like peptide-1 receptor agonists and bariatric surgery on pulmonary hemodynamics and standardize the use of hypoxic burden as a clinical endpoint.
科研通智能强力驱动
Strongly Powered by AbleSci AI